Neutropenia

Jump to navigation Jump to search

Template:DiseaseDisorder infobox

WikiDoc Resources for Neutropenia

Articles

Most recent articles on Neutropenia

Most cited articles on Neutropenia

Review articles on Neutropenia

Articles on Neutropenia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Neutropenia

Images of Neutropenia

Photos of Neutropenia

Podcasts & MP3s on Neutropenia

Videos on Neutropenia

Evidence Based Medicine

Cochrane Collaboration on Neutropenia

Bandolier on Neutropenia

TRIP on Neutropenia

Clinical Trials

Ongoing Trials on Neutropenia at Clinical Trials.gov

Trial results on Neutropenia

Clinical Trials on Neutropenia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Neutropenia

NICE Guidance on Neutropenia

NHS PRODIGY Guidance

FDA on Neutropenia

CDC on Neutropenia

Books

Books on Neutropenia

News

Neutropenia in the news

Be alerted to news on Neutropenia

News trends on Neutropenia

Commentary

Blogs on Neutropenia

Definitions

Definitions of Neutropenia

Patient Resources / Community

Patient resources on Neutropenia

Discussion groups on Neutropenia

Patient Handouts on Neutropenia

Directions to Hospitals Treating Neutropenia

Risk calculators and risk factors for Neutropenia

Healthcare Provider Resources

Symptoms of Neutropenia

Causes & Risk Factors for Neutropenia

Diagnostic studies for Neutropenia

Treatment of Neutropenia

Continuing Medical Education (CME)

CME Programs on Neutropenia

International

Neutropenia en Espanol

Neutropenia en Francais

Business

Neutropenia in the Marketplace

Patents on Neutropenia

Experimental / Informatics

List of terms related to Neutropenia

Editor-in-Chief: Aric Hall, M.D. Beth Israel Deaconess Medical Center, Boston, MA[1]

Overview

Neutropenia (or neutropaenia, adjective neutrop(a)enic) is a hematological disorder characterized by an abnormally low number of neutrophil granulocytes (a type of white blood cell). Neutrophils usually make up 50-70% of circulating white blood cells and serve as the primary defense against infections by destroying bacteria in the blood. Hence, patients with neutropenia are more susceptible to bacterial infections and without prompt medical attention, the condition may become life-threatening. Neutropenia can be acute or chronic depending on the duration of the illness. A patient has chronic neutropenia if the condition lasts for greater than 3 months. It is sometimes used interchangeably with the term leukopenia. However, neutropenia is more properly considered a subset of leukopenia as a whole.

Classification

There are 3 general guidelines used to classify the severity of neutropenia based on the absolute neutrophil count (ANC) measured in cells per microliter of blood:

  • Mild neutropenia (1000 < ANC < 1500) — minimal risk of infection
  • Moderate neutropenia (500 < ANC < 1000) — moderate risk of infection
  • Severe neutropenia (ANC < 500) — severe risk of infection.

NOTE: These are ranges for Caucasians. Neutropenia in black individuals is defined as ANC < 1200. This is a not well known fact that results in overdiagnosis of neutropenia in black population.[1]

Types

Severe chronic neutropenia may be present at birth (congenital neutropenia) or may occur at any stage in life (acquired neutropenia). There are several types of severe chronic neutropenia:

Severe congenital neutropenia — a rare inherited form of the disease usually detected soon after birth. It affects children mainly and may result in premature loss of teeth and peremptory gum infections. The most severe form of chronic congenital neutropenia is known as Kostmann’s syndrome. It is genetically heterogeneous. Most commonly, it arises as a result of new, autosomal dominant mutations in the gene, ELA2, encoding the neutrophil granule protease, neutrophil elastase, NE. The gene responsible for many cases of autosomal recessively inherited severe congenital neutropenia is HAX1. The mechanism for congenital neutropenia is not well-understood. There is evidence that mutations in neutrophil elastase, or in other genes associated with syndromic forms of neutropenia, disrupt its intracellular trafficking. Apoptosis may be a final effector for neutropenia, but the original studies from Dale and Aprikian supporting this pathway were retracted.

Cyclic neutropenia — tends to occur every three weeks and lasting three to six days at a time due to changing rates of cell production by the bone marrow. It is often present among several members of the same family. Cyclic neutropenia is also the result of autosomal dominantly inherited mutations in ELA2, the gene encoding neutrophil elastase.

Idiopathic neutropenia — a rare form of neutropenia which develops in children and adults usually in response to an illness. It is diagnosed when the disorder cannot be attributed to any other diseases and often causes life-threatening infections.

Myelokathexis — a rare form of inherited autosomal dominant disease associated with severe neutropenia. Some but not all patients have Warts, Hypogammaglobulinemia, and recurrent Infections. Therefore myelokathexis is also known as the W.H.I.M. syndrome. In spite of severe neutropenia (low number of neutrophils) in peripheral blood of myelokathexis patients, their bone marrow is hypercellular and it is packed with mature neutrophils indicating an impaired mobilization of hematopoietic cells in this disorder. Truncating mutations in the human cytokine receptor CXCR4 gene were identified in most of the families afflicted by myelokathexis. The molecular mechanism is not yet defined. Recent reports demonstrate that CXCR4 mutations appear to result in an increased sensitivity of bone marrow hematopoietic cells to its ligand, a stromal-derived growth factor SDF-1 that provides proliferative and survival signals.

Autoimmune neutropenia — most common in infants and young children where the body identifies the neutrophils as enemies and makes antibody to destroy them. This form usually lessens in severity within two years of diagnosis.

Drug-induced neutropenia — Many drugs can cause agranulocytosis (complete absence of white cells) and neutropenia. Many anti-neoplastic drugs cause agranulocytosis and neutropenia by bone marrow suppression. Neutropenia and agranulocytosis can also result from antibody or complement-mediated damage to the stem cells. Some drugs may cause increased peripheral destruction of white cells. About 75% of all cases of agranulocytosis in the United States are related to medication. Clozapine, procainamide, anti-thyroid drugs (e.g. methimazole, and sulfasalazine are at the top of the list of drugs causing this problem, but many others (such as antiepileptics) have been implicated.

Differential diagnosis of causes of neutropenia

Causes can be divided into the following groups:

There is usually a mild neutropenia in viral infections.

Signs and symptoms

Neutropenia can go undetected, but is generally discovered when a patient has developed severe infections or sepsis. Some common infections can take an unexpected course in neutropenic patients; formation of pus, for example, can be notably absent, as this requires circulating neutrophil granulocytes.

Some common symptoms of neutropenia include:

Diagnosis

Low neutrophil counts are detected on a full blood count. A peripheral blood smear is often useful to evaluate for abnormal morphology of the visible cells, which may help suggest the diagnosis. Evaluation for metabolic abnormalities, genetic causes neutropenia, and/or other underlying metabolic or toxic causes will often follow. When the etiology is uncertain, or serious causes such as malignancy and marrow replacement are suspected, bone marrow biopsy is often necessary.

Therapy

There is no ideal therapy for neutropenia, but recombinant G-CSF (granulocyte-colony stimulating factor) can be effective in chemotherapy patients, in patients with congenital forms of neutropenia including severe congenital neutropenia, autosomal recessive Kostmann's syndrome, cyclic neutropenia, myelokathexis, and some other causes...

See also

References

  1. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007). "Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences". Ann. Intern. Med. 146 (7): 486–92. PMID 17404350.

Template:Hematology Template:SIB

de:Neutropenie it:Neutropenia nl:Neutropenie sq:Neutropenia